Journal
GUT
Volume 69, Issue 12, Pages 2093-2112Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/gutjnl-2020-322368
Keywords
-
Categories
Funding
- National Taiwan University Hospital [NTUH 107-P05, 109-P03]
- Ministry of Science and Technology, Executive Yuan, ROC, Taiwan [TCTC 108-2321-B-002 -040, MOST 108-2314-B-002 -187, 108-2314-B-002 -209]
- Ministry of Health and Welfare of Taiwan [MOHW107-TDU-B-211-123002, MOHW108-CDC--C-114-112102]
- Center of Precision Medicine from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan [NTU-107L9014-1]
- Liver Disease Prevention & Treatment Research Foundation, Taiwan
- Gastroenterological Society of Taiwan (GEST)
- Takeda Taiwan Co. Ltd [APTC-01]
- Eisai Co. Ltd
- Swiss Pharmaceutical Co., Ltd [APTC-02]
- Panion & BF Biotech Inc. [APTC-03]
- Harvester Trading Co. LTD [APTC-04]
- Office of Research and Development Medical Research Service Department of Veterans Affairs, Public Health Service grant - Texas Medical Center Digestive Diseases Center [DK56338]
- Australian Federal Government
- Sutherland Medical Research Foundation
Ask authors/readers for more resources
Objective A global consensus meeting was held to review current evidence and knowledge gaps and propose collaborative studies on population-wide screening and eradication of Helicobacter pylori for prevention of gastric cancer (GC). Methods 28 experts from 11 countries reviewed the evidence and modified the statements using the Delphi method, with consensus level predefined as >= 80% of agreement on each statement. The Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach was followed. Results Consensus was reached in 26 statements. At an individual level, eradication of H. pylori reduces the risk of GC in asymptomatic subjects and is recommended unless there are competing considerations. In cohorts of vulnerable subjects (eg, first-degree relatives of patients with GC), a screen-and-treat strategy is also beneficial. H. pylori eradication in patients with early GC after curative endoscopic resection reduces the risk of metachronous cancer and calls for a re-examination on the hypothesis of 'the point of no return'. At the general population level, the strategy of screen-and-treat for H. pylori infection is most cost-effective in young adults in regions with a high incidence of GC and is recommended preferably before the development of atrophic gastritis and intestinal metaplasia. However, such a strategy may still be effective in people aged over 50, and may be integrated or included into national healthcare priorities, such as colorectal cancer screening programmes, to optimise the resources. Reliable locally effective regimens based on the principles of antibiotic stewardship are recommended. Subjects at higher risk of GC, such as those with advanced gastric atrophy or intestinal metaplasia, should receive surveillance endoscopy after eradication of H. pylori. Conclusion Evidence supports the proposal that eradication therapy should be offered to all individuals infected with H. pylori. Vulnerable subjects should be tested, and treated if the test is positive. Mass screening and eradication of H. pylori should be considered in populations at higher risk of GC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available